Indivior PLC $INDV Shares Newly Acquired by NINE MASTS CAPITAL Ltd

NINE MASTS CAPITAL Ltd acquired a new position in shares of Indivior PLC (NASDAQ:INDV – Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 20,000 shares of the company’s stock, valued at approximately $717,000.

A number of other large investors have also recently made changes to their positions in INDV. Two Seas Capital LP raised its holdings in Indivior by 5.5% in the third quarter. Two Seas Capital LP now owns 3,671,072 shares of the company’s stock valued at $131,608,000 after acquiring an additional 191,579 shares in the last quarter. Assenagon Asset Management S.A. grew its holdings in Indivior by 129.8% during the 3rd quarter. Assenagon Asset Management S.A. now owns 3,540,344 shares of the company’s stock worth $126,921,000 after acquiring an additional 1,999,416 shares in the last quarter. Newtyn Management LLC acquired a new position in Indivior during the 2nd quarter worth approximately $53,577,000. Danske Bank A S grew its holdings in Indivior by 90.8% during the 3rd quarter. Danske Bank A S now owns 1,101,966 shares of the company’s stock worth $39,505,000 after acquiring an additional 524,489 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. purchased a new stake in shares of Indivior in the 2nd quarter valued at approximately $14,781,000. 60.33% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, CAO Woodrow D. Anderson bought 1,500 shares of the stock in a transaction dated Thursday, August 27th. The stock was acquired at an average price of $35.69 per share, for a total transaction of $53,535.00. Following the acquisition, the chief accounting officer owned 27,638 shares in the company, valued at approximately $986,400.22. This represents a 5.74% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 0.74% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the stock. Weiss Ratings lowered shares of Indivior from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, September 24th. Wall Street Zen cut shares of Indivior from a “strong-buy” rating to a “buy” rating in a research report on Saturday, October 31st. Zacks Research upgraded shares of Indivior from a “hold” rating to a “strong-buy” rating in a research note on Friday, October 2nd. Barclays increased their target price on Indivior from $43.00 to $45.00 and gave the company an “overweight” rating in a report on Wednesday, October 28th. Finally, Craig Hallum restated a “buy” rating and issued a $53.00 price target on shares of Indivior in a research note on Tuesday, August 4th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $46.40.

View Our Latest Stock Report on Indivior

Indivior Stock Up 0.2%

INDV stock opened at $28.21 on Monday. The business has a 50 day moving average price of $34.24 and a 200 day moving average price of $35.48. The stock has a market cap of $3.33 billion, a price-to-earnings ratio of 7.88 and a beta of 0.84. Indivior PLC has a fifty-two week low of $27.68 and a fifty-two week high of $42.81.

Indivior (NASDAQ:INDV – Get Free Report) last announced its quarterly earnings results on Thursday, October 29th. The company reported $1.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.06 by $0.26. Indivior had a negative return on equity of 418.04% and a net margin of 32.75%. The firm had revenue of $356.00 million during the quarter, compared to the consensus estimate of $329.35 million. As a group, sell-side analysts anticipate that Indivior PLC will post 3.66 EPS for the current year.

Indivior Dividend Announcement

The business also recently announced a special dividend, which was paid on Friday, November 6th. Stockholders of record on Friday, October 30th were issued a $8.13 dividend. The ex-dividend date was Tuesday, November 3rd.

Indivior Profile

(Free Report)

Indivior is a specialty pharmaceutical company focused on developing and providing treatments for substance use disorders and serious mental illness. Its products include medicines for opioid use disorder, such as Sublocade, a long-acting injectable form of buprenorphine, and Suboxone, a buprenorphine-and-naloxone treatment. The company also markets Opvee, a nasal spray used to reverse opioid overdose, and Perseris, a long-acting injectable treatment for schizophrenia. Indivior develops additional therapies through its research and development programs.

Featured Stories

Want to see what other hedge funds are holding INDV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Indivior PLC (NASDAQ:INDV – Free Report).

Institutional Ownership by Quarter for Indivior (NASDAQ:INDV)

Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.